Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil–based chemotherapy in colorectal cancer

Chen, William Tzu Liang; Yang, Tien-Yu; Chen, Hung-Chang; Chen, Hong Hwa; Chiang, Hua Che; Lin, Tung-Yi; Yeh, Chia-Yi; Chen, Jen Shi; Hsiao, Koung Hung; Kuo, Min-Liang

doi:10.1016/j.nutres.2014.06.010

Cited by 34 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The safety and effectiveness of MB‐6 (extracted from some plants such as curcumin) in combination with chemotherapy in 60 metastatic colorectal cancer (mCRC) patients was evaluated by Chen et al (). Twenty‐nine patients received 6 × 320 mg oral capsules of MB‐6 three times a day and 5‐FU plus oxaliplatin (FOLFOX4) chemotherapy regimen every 2 weeks for 16 weeks.…”

Section: Introductionmentioning

confidence: 99%

Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer

Jalili‐Nik

Soltani²,

Moussavi

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cause of cancer-related deaths worldwide. Hence there is a need to identify new therapeutic agents that improve the current repertoire of chemotherapeutic drugs. The antitumor activity of curcumin has been reported for several tumors, including CRC. A recent phase I trial showed that curcumin is safe and tolerable adjunct to FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in patient-derived colorectal liver metastases at doses up to 2 g daily. Another trial revealed the effect of combining curcumin with FOLFOX in patients with inoperable colorectal cancer. The aim of current review was to summarize the current knowledge about possible molecular mechanisms of curcumin in CRC with particular emphasis on preclinical and early clinical studies of colorectal cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer

Jalili‐Nik

Soltani²,

Moussavi

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…In the study of Chen et al [15], 72 patients with metastatic colorectal cancer received leucovorin, 5-fluorouracil and oxaliplatin in combination with MB-6 or placebo for 16 weeks. MB-6 is a combination of soybean, green tea, Antrodia camphorata mycelia, spirulina, grape seed and curcumin.…”

Section: Introductionmentioning

confidence: 99%

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

Mahammedi¹,

Planchat²,

Pouget³

et al. 2016

Oncology

118

View full text Add to dashboard Cite

Objectives: Favorable phase I results justified this pilot phase II study to assess the efficacy of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC). Methods: Thirty patients with progressing CRPC and a rising prostate-specific antigen (PSA) received docetaxel/prednisone in standard conditions for 6 cycles in combination with per os curcumin, 6,000 mg/day (day -4 to day +2 of docetaxel). The co-primary endpoint was the overall response rate determined by PSA and target assessments. An ancillary study assessed the seric values of chromogranin A (CgA) and neuron-specific enolase (NSE). Results: Twenty-six patients received the scheduled treatment, 2 progressed and 2 died before the end of treatment. A PSA response was observed in 59% of patients (14% of PSA normalization) and achieved within the first three cycles for 88% of responders. Partial response was reached for 40% of evaluable patients. The regimen was well tolerated, and no adverse event was attributed to curcumin. Twenty patients were 100% curcumin compliant. The PSA level and objective response rate were not correlated with the serum values of CgA and NSE. Conclusion: This study produced additional data on curcumin as a treatment for cancer, with a high response rate, good tolerability and patient acceptability, justifying the interest to conduct a randomized trial.

show abstract

“…A large body of literature now exists indicating that the herbal medicines or natural compounds may be feasible for use as potent chemopreventive drugs (36,37). The goal of the present study was to assess whether psoralen, an active ingredient extracted from Psoralea corylifolia, may reverse MDR by modulating the function of P-gp.…”

Section: Discussionmentioning

confidence: 99%

Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells

Jiang

Wang

Chen

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

The resistance of cancer to chemotherapeutic agents is a major obstacle during chemotherapy. Clinical multidrug resistance (MDR) is commonly mediated by membrane drug efflux pumps, including ATP‑binding cassette subfamily B member 1, also termed P-glycoprotein (P-gp). P-gp is a membrane transporter encoded by the MDR1 gene. The current study aimed to investigate the impact of psoralen on the expression and function of P‑gp. The 10% inhibitory concentration (IC10) of psoralen, and its capacity to reduce MDR in adriamycin (ADR)‑resistant MCF‑7/ADR cells were determined using MTT assay. The ability of psoralen to modulate the transport activity of P‑gp in MCF‑7/ADR cells was evaluated by measuring the accumulation and efflux of rhodamine 123 (Rh 123) and adriamycin with flow cytometry. The present study evaluated the mRNA level of MDR1 in MCF‑7 and MCF‑7/ADR cells treated with psoralen using reverse transcription-quantitative polymerase chain reaction. The protein expression level of P‑gp was examined by western blot analysis. The current study demonstrated that the IC10 of psoralen in MCF‑7/ADR cells was 8 µg/ml. At 8 µg/ml, psoralen reduced MDR and the sensitivity of the MCF‑7/ADR cells to ADR compared with untreated cells. Additionally, psoralen significantly increased the intracellular accumulation of ADR and Rh 123. However, the IC10 of psoralen did not affect the protein expression levels of P‑gp or mRNA levels of MDR1 (P>0.05). Psoralen reduces MDR by inhibiting the efflux function of P‑gp, which may be important for increasing the efficiency of chemotherapy and improving the clinical protocols aiming to reverse P-gp-mediated MDR.

show abstract

Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil–based chemotherapy in colorectal cancer

Cited by 34 publications

References 26 publications

Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer

Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells

Contact Info

Product

Resources

About